Background In breast cancers, the gene for the growth factor receptor HER2 can be ampliWed leading to increased aggressiveness and metastasis formation. The monoclonal antibody trastuzumab prolongs relapse-free survival highly signiWcantly but eventually many patients relapse. Method In this study, CETC were monitored using the Maintrac ® method during adjuvant trastuzumab treatment and during subsequent treatment with capecitabine/lapatinib.
The HER2/neu gene, coding for a growth factor receptor which is over-expressed in these patients, is ampliWed in approximately 25% of breast cancer patients, showing highly aggressive disease. Trastuzumab is a monoclonal antibody targeted to the external domain of this growth factor receptor and has been shown to be eVective in metastatic breast cancer (Seidman et al. 2001) , with clinical beneWt seen in about half of the patients with HER2/neupositive disease (Piccart-Gebhart et al. 2005) . Trastuzumab has also shown a highly signiWcant increase in disease-free survival and overall survival in three adjuvant trials (NCCTG N 9831, NSABP B-31 and HERA-trial) Viani et al. 2007) . Comparisons suggest that trastuzumab given concurrently with taxanes may have superior eYcacy than given sequentially after chemotherapy (Romond et al. 2005) . In the neoadjuvant treatment, addition of trastuzumab to chemotherapy has increased pathological complete response (pCR) from 26% (P (paclitaxel) £ 4 followed by FEC (Xuorouracil/epirubicin/ cyclophosphamide) £ 4) to 65% (P £ 4 followed by FEC £ 4 together with trastuzumab) (Buzdar et al. 2005) with pCR still being a marker of good survival (Lazaridis et al. 2008) . Thus, the fate of patients with HER2/neu-positive disease has been improved, but eventually most patients relapse (Colozza et al. 2007) .
To date, it is not known how long trastuzumab should be given, whether cells become resistant to trastuzumab due to loss of receptor expression (Nahta and Esteva 2006) or to a modiWed receptor, no longer accessible to the antibody (Kumar 2007) or other ways of resistance (Berns et al. 2007; Pályi-Krekk et al. 2007 ).
This has prompted research for other molecules still active when trastuzumab does not work any more (Cardoso et al. 2002) . Lapatinib (Mukherjee et al. 2007 ) is such a molecule, a dual tyrosine kinase inhibitor that blocks phosphorylation of both epidermal growth factor receptor (EGFR) and HER2/neu (Nahta et al. 2007) . Also, lapatinib is speciWcally and exclusively bound to these receptors and has a slow oV-rate for both ErbB1 and ErbB2 (Ito et al. 2007 ). Preclinical studies showed that lapatinib may cause apoptosis in HER2/neu-overexpressing cells even if the cells have been previously exposed to trastuzumab (Konecny et al. 2006) . In clinical trials, objective responses were obtained in heavily pre-treated patients with HER2/neu-overexpressing metastatic breast cancer (Burris 2004 ) and a combination of lapatinib and capecitabine was superior to capecitabine alone (Tripathy 2007 ). We present here two cases of heavily pre-treated patients in whom trastuzumab was not capable of eliminating the CETC in the blood and the disease progressed. But treatment with a combination of capecitabine and lapatinib led to immediate elimination of all CETC.
Methods
Two patients were monitored for CETC and the response of these cells to the diVerent therapeutic regimen during the course of disease. One millilitre blood samples anticoagulated with ethylene diamine tetra acidic acid (EDTA) were drawn before each new therapeutic manipulation and at each visit during subsequent observation.
Red blood cells were lysed with ammonium chloride (Qiagen, Hilden, Germany). For detection of CETC white cells from the sediment were subject to the MAINTRAC ® analysis diluting the pellet in 500 l phosphate buVered salt (PBS) solution pH 7.4 adding 12.5 l of Xuoresein-isothiocyanate (FITC)-conjugated mouse anti-human epithelial antibody (HEA) and 5 l phycoerythrin (PE) labelled anti-CD45 (Miltenyi Bergisch Gladbach, Germany) simultaneously for 15 min in the dark. Analysis of red and green Xuorescence of the cells was performed using a Laser Scanning Cytometer ® (Compucyte Corporation, Cambridge, MA, USA) enabling relocation of cells for visual examination of vital epithelial cells as extensively described previously (Pachmann et al. 2005b) or an image analysis system of Olympus ScanR which gave identical results.
A deWned volume of the cell suspension was applied to a deWned area on a slide or in a microtiter well and laser scanning or image analysis started of this area. Cells were detected by their forward scatter property, and red and green Xuorescence recorded in the LSC or images taken in the ScanR. Epithelial cells stained with green Xuorescence, exclusively surface-located, and normal blood cells stained with CD45 red Xuorescence (Fig. 1) . The epithelial cells selected by their green Xuorescence were relocated and analysed for vitality. Only vital cells were counted.
Numbers of CETC were calculated per ml and varied between undetectable and 100,000. These numbers are tenfold higher than numbers obtained using the CellSearch system (Meng et al. 2004 ) but with more recent system numbers getting close to our results are obtained (Nagrath et al. 2007 ). The diVerence may be due to omission of magnetic separation which leads to a loss of speciWc cells together with the enrichment process, as discussed extensively in a previous study (Pachmann et al. 2005b) . Normal blood cells could easily be distinguished from epithelial antigen-positive cells. No live epithelial cells were detected in 97% of healthy donors and in 38/40 patients with haematological malignancies (Pachmann et al. 2005b , Camara et al. 2007 ).
Results
The Wrst patient treated with neoadjuvant chemotherapy was a poor responder according to our criteria published in Camara et al. (2007) with hardly a tenfold reduction in CETC and a subsequent re-increase. CETC numbers changed only marginally during the combined taxane/trastuzumab treatment typically associated with early relapse in HER2/neu-positive patients according to our observations. She then had surgery and subsequent treatment with trastuzumab for 1 year. Brain metastases detected already at diagnosis progressed after surgery and required radiotherapy. Still, trastuzumab was given 3-weekly as planned for 1 year. CETC numbers slowly started to decrease during the year of trastuzumab treatment (Fig. 2) . Stable disease was observed during this year. Trastuzumab was halted as planned whereupon she developed skin metastases and her brain metastases progressed. She, therefore, received capecitabine for six courses together with lapatinib. Already upon the Wrst cycle of capecitabine/lapatinib cell numbers decreased to below the threshold of detection and remained undetectable for the next 12 weeks but then started re-increasing together with a renewed progress of the brain metastases (Fig. 2) .
In the second patient, after breast-conserving surgery, her CETC levels in blood rose to extremely high values. She was treated with adjuvant chemotherapy with EC and taxane/trastuzumab. Subsequently, she was treated for one more year of trastuzumab within the HERA-trial with an increase in CETC (Fig. 3) . Trastuzumab was stopped after 1 year and a local relapse with skin involvement was diagnosed 2 months later which was treated with mastectomy ( Fig. 3) . Trastuzumab was re-initiated for 3 months but she again developed skin metastases during the following time which eventually required surgery. She then received capecitabine/lapatinib for six cycles upon which her CETC numbers fell to below the threshold of detection and have remained that low until now (Fig. 3) . Her metastases have not shown further progress.
Conclusions
Monitoring of these CETC has shown to provide a valuable tool for analysis of the eVect of therapeutic agents (Camara et al. 2007; Lobodasch et al. 2007 ). Thus, the response of CETC to the Wrst cycles of neoadjuvant therapy highly correlates with tumour size reduction (Pachmann et al. 2005a ) and this also results in an improved relapse-free survival in these patients (Camara et al. 2007) , whereas lack of response in the neoadjuvant setting to anthracycline is a strong predictor of relapse independent of further treatment.
This was, indeed, also true for the Wrst patient, who presented with an inXammatory breast cancer, which is frequently accompanied by HER2/neu-positivity (GonzalezAngulo et al. 2007 ). She had very high CETC numbers from the beginning and already initially presented with brain metastases. FEC was only able to reduce her CETC moderately and the following combined treatment of taxane and trastuzumab led to a re-increase in CETC. We interpreted this as release of cells from the primary tumour during tumour tissue disintegration. Cells in the brain that had settled already early showed growth (Lin and Winer 2007) developing as progressive brain metastases in spite of subsequent trastuzumab treatment and more brain metastases appeared at the end of trastuzumab treatment. Initially, no extra-cranial growth was observed during the trastuzumab treatment (Kirsch et al. 2005 ), but CETC numbers only marginally decreased without being completely eliminated. CETC presented at diagnosis or released during neoadjuvant therapy may have contained a subpopulation of cells that were only temporarily silenced by trastuzumab treatment but eventually were able to metastasize and skin metastases developed. Due to disease progress capecitabine/lapatinib therapy (Bilancia et al. 2007 ) was initiated, and there was an immediate and complete elimination of CETC indicating an excellent response to this treatment (Pachmann et al. 2008 ) at least in the peripherally circulating cells. This did, however, not translate into a long-lasting reduction of metastatic disease and additional skin metastases appeared (<4 months) accompanied by reappearance of CETC.
The second patient showed an extremely high CETC dissemination after surgery and relapsed early after adjuvant chemotherapy. Cell numbers remained high and even increased during the following trastuzumab treatment. Thus trastuzumab was not able to eliminate circulating tumour cells. But its ability to drive tumour cells into G1 (G0) of We have presented here two cases of patients with HER2/neu-positive breast cancer who showed progress during treatment with trastuzumab. In both cases, CETC showed no, or only marginal, reduction during treatment with the antibody, indicating that in these patients trastuzumab possibly inhibited cell growth but was not capable of eliminating CETC. Thus, binding of the antibody to the relevant cells seems not or hardly to induce apoptosis or cell death but instead may prevent cells in blood from settling and perhaps multiplying.
A Wnal trial with capecitabine and lapatinib for the Wrst time completely eliminated all CETC in the Wrst patient with an initial diagnosis of inXammatory breast cancer.
Even if treatment was no longer eVective in the manifest skin metastases, our results contribute indications that lapatinib is eVective in combination with capecitabine (Geyer et al. 2006) and indeed leads to cell elimination (Spector et al. 2005 ) even in inXammatory breast cancer (Cristofanilli et al. 2006) .
The same was true for the second patient who received trastuzumab after adjuvant treatment. Her circulating cells showed an increase in CETC numbers during trastuzumab with local relapse. EVective elimination was only observed with the combination of capecitabine and lapatinib, leading to cell elimination possibly by cell death due to eVective inhibition of signalling pathways (Wood et al. 2004) .
Our results proved the Wrst observation that the anti-HER2/neu antibody results in a temporary proliferation stop but rarely completely eliminates the tumour cells. These cells may be responsible for eventual metastasis formation after antibody withdrawal. In contrast, lapatinib may, especially in the context of additional cell toxic drugs, induce cell death under clinical relevant conditions. Therefore, these results might warrant earlier application of lapatinib, for example, in combination with capecitabine in the clinical setting in order to eliminate the source of metastases, the CETC, before they can settle and then may become less accessible to elimination. Treatment success can be controlled monitoring the response of CETC.
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